The Drug Class That Didn't Exist Until Yesterday

BMS still needs to deliver on that front. The EXCALIBER-RRMM trial, a randomized phase 3 study comparing iberdomide's combo against a control arm, has dual primary endpoints of MRD negativity and progression-free survival (PFS). The MRD data were strong enough for an interim win; the PFS and overall survival readouts are still cooking.

If those numbers come in strong, BMS converts an accelerated approval into a full one. If they don't, the FDA can pull it. That's the deal with accelerated approvals: you get to market early, but you're essentially on probation.

The Jar Lid Analogy, Explained

So why build a new class if the old drugs work on the same target? Because cancer cells are stubborn, and they adapt.

Patients who've been treated with lenalidomide or pomalidomide can develop resistance. Their myeloma cells learn to shrug off the cereblon manipulation. Iberdomide was engineered to overcome that wall. It grabs cereblon outside the usual binding pocket, forcing a stronger shape change (a "closed" conformation, in science-speak) that old IMiDs can't reliably trigger. The result is faster, more potent destruction of the proteins myeloma needs.

This isn't just a theoretical upgrade. The clinical rationale for iberdomide rests on activity in patients whose disease has already stopped responding to IMiDs, which is exactly the population piling up as more patients receive lenalidomide in earlier lines of treatment.

BMS Is Betting Big on This Platform

Iberdomide isn't a one-off. It's the tip of a CELMoD iceberg that Bristol Myers Squibb has been building for years.

The company has mezigdomide in two phase 3 studies (SUCCESSOR-1 and SUCCESSOR-2) for relapsed/refractory myeloma, positioning it as a sibling to iberdomide deeper in the treatment sequence. Then there's golcadomide, a CELMoD aimed at lymphoma rather than myeloma. Across the franchise, BMS is trying to do for cereblon modulators what it did for checkpoint inhibitors with Opdivo: own the category.

As of July 2026, BMS reported 49 compounds in development across more than 40 disease areas. But iberdomide holds a special place in the portfolio because it addresses a critical corporate need: near-term revenue. The company is staring down patent cliffs on its legacy drugs, and analysts want to see launchable assets contributing by 2026 and 2027, not just promising data slides at medical conferences.

A Crowded Neighborhood, but a Different House

Multiple myeloma in 2026 is not the same disease it was five years ago. The treatment landscape has exploded with options.

Frontline patients now get anti-CD38 quadruplet combos like Dara-VRd. In the relapsed setting, bispecific antibodies (teclistamab, elranatamab, linvoseltamab, talquetamab) and CAR-T cell therapies have stormed onto the scene, giving doctors more tools than ever for patients who relapse early or have high-risk disease.

So where does iberdomide fit? Its sweet spot is the patient who's had one prior line of therapy (including a proteasome inhibitor and an IMiD) and isn't necessarily a candidate for CAR-T, which requires manufacturing time that rapidly progressing patients may not have. An oral backbone drug that pairs with daratumumab could slot neatly into everyday practice, especially at community oncology centers that may not have access to specialized cell therapy programs.

Outside BMS, competition in the CELMoD space is thinner than you'd expect. C4 Therapeutics' cemsidomide is the most visible external challenger, with a phase 2 program in relapsed myeloma. For now, BMS effectively owns the category.

The Bottom Line

The approval of Zenbexus is significant for two reasons that go beyond one drug for one disease. First, it validates targeted protein degradation as a therapeutic strategy in a way that a clinical-stage pipeline alone never could. Regulatory approval carries a different weight than conference posters. Second, it gives BMS a tangible answer to the question Wall Street keeps asking: what fills the gap when your older blockbusters lose exclusivity?

The answer, at least partly, is a new class of drugs that grabs the same molecular machinery as the old ones, but grips it harder and turns it faster. Whether that translates into longer survival data and sustained commercial success is the next chapter of this story. The EXCALIBER-RRMM trial's PFS readout will be the real test.

For patients with relapsed myeloma, though, a new option is a new option. And this one comes with a mechanism the field has never had before.